SEP 26, 2016 10:51 AM PDT

Circadian Rhythm Gene Can Influence Breast Cancer Progression

WRITTEN BY: Jennifer Ellis
Everyone knows sleep is important. Getting a good night’s sleep resets your brain, allows for efficient cell repair and aids in effective digestion. Interruptions in sleep/wake cycles, otherwise known as the circadian rhythm, have long been thought to contribute to cancer progression due to changes at the cell and tissue level.
 
Scientists at the National Cancer Institute have recently discovered that one of the circadian rhythm genes can specifically affect breast cancer metastasis. Breast cancer is one of the most common diagnoses in women in the United States, and breast cancer metastasis is the second leading cause of death in women. It is commonly known that the primary tumor is not what causes the high mortality rates in cancer; it is the metastasis of that tumor to other body parts. Metastasis can be hard to contain, and depending on the tumor type, might not have targeted therapies to treat.
Sections of myometrial muscle infiltrated by metastatic carcinoma. (Cesar A. Moran, CancerNetwork)
To complicate things even further, there are several different subtypes of malignancy that can affect tumor progression and treatment options. Two subtypes of breast cancer, ER+ (estrogen receptor-positive) and HER+ (human epidermal growth factor-positive), have targeted therapies specifically developed to these types of tumors even after they have disseminated throughout the body. These treatments target the tumor cells directly and negate the need for general therapies such as chemotherapy.

However, ER- and HER- tumor types do not respond well to these therapies and have a higher chance of metastasis and poor survival prognosis. A better understanding of the biology and genetics behind these ER- and HER- tumors would provide the basis for new targeted therapies and clinical treatments to improve the outcome of diagnosis and malignancy in these patients.
 
Studying crosses of genetically engineered mice with highly metastatic mammary tumors with those containing low frequency metastatic tumors provided gene signatures consistent with the ER- cancer subtype and led to the identification of Arntl2, a known circadian rhythm gene, as a metastatic susceptibility gene. Kent Hunter, one of the primary authors of the study and Senior Investigator at NCI, notes that this association suggests circadian rhythm plays a role in both the cause and progression of this very aggressive form of breast cancer.
Identification of the circadian rhythm Arntl2 gene and its relationship to cancer metastases (Siracusa LD, Bussard KM; 2016)
Based on mapping data from the cross, researchers genotyped an area that highlighted the Arntl2 gene as a primary cause for progressive metastasis in the mice and related cell lines. Further knockout experiments and association-based patient cohort studies were done to validate the Arntl2 gene as a causative gene to metastatic-specific cancer progression in the ER- subtype.

This study, published in PLOS Genetics, sheds light on metastasis and the many factors that enable a primary tumor to spread. Metastasis is a complicated process influenced by many factors, such as obtaining invasive and migratory abilities, gaining entry into the lymphatic system, and colonization of cells in a new environment. Given the different factors that go into cancer progression, it has become evident that there are several outside influencers and biological processes that can positively or negatively affect tumor progression.

Circadian rhythm disruption has been indicated in previous studies to increase breast cancer risk and survival rates based on epidemiological and gene expression studies. However, there have not been any causal effects shown until now. Hunter and team were able to prove that Arntl2 has a direct effect on the metastasis of ER- breast cancer. These findings provide a genetic basis for inherited susceptibility of cancer metastasis and emphasize the potential of incorporating behavioral adjustments such as more sleep and sustained sleep/wake cycles into cancer treatment.

Sources: PLOS Genetics, NCI, Reuters, Arntl2 Image
About the Author
Master's (MA/MS/Other)
I love all things science and am passionate about bringing science to the public through writing. With an M.S. in Genetics and experience in cancer research, marketing and technical writing, it is a pleasure to share the latest trends and findings in science on LabRoots.
You May Also Like
OCT 07, 2022
Drug Discovery & Development
A wearable sensor that can monitor tumor size changes in real-time
A wearable sensor that can monitor tumor size changes in real-time
As cancer drugs are developed, one important process the drug goes through is testing in experimental animals. The use o ...
OCT 31, 2022
Cancer
Pumpkins: A Trick or a Treat for Cancer?
Pumpkins: A Trick or a Treat for Cancer?
Cancer is a disease that impacts the whole person, wreaking havoc on an individual’s emotional and physical well-b ...
NOV 15, 2022
Genetics & Genomics
Revealing the Mutations that Make Melanoma Immortal
Revealing the Mutations that Make Melanoma Immortal
Telomeres cap the ends of chromosomes, preventing breakage. Some cancer cells can use those protective caps to their adv ...
NOV 23, 2022
Cannabis Sciences
Why researchers have hope that cannabis may help fight ovarian cancer
Why researchers have hope that cannabis may help fight ovarian cancer
There's a positive, growing link between cannabis and the fight against ovarian cancer. Here's why researchers are optim ...
DEC 12, 2022
Cancer
Most Adults Don't Know Alcohol Increases Cancer Risk
Most Adults Don't Know Alcohol Increases Cancer Risk
Many of us indulge in alcohol in some form or another.  The frequency and type of alcohol consumed range from an oc ...
DEC 19, 2022
Cancer
TIL Therapy for Advanced Melanoma Extends Survival Over Ipilimumab
TIL Therapy for Advanced Melanoma Extends Survival Over Ipilimumab
Immune checkpoint inhibitors (ICIs) have become a treatment option for many patients with advanced melanoma.  Still ...
Loading Comments...